PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Copaiba oil demonstrates bactericidal and/or bacteriostatic effects in vitro; C. officinalis showed antimicrobial effects similar to chlorhexidine in one study [PMID:29193389]. It specifically shows bacteriostatic activity against Streptococcus mutans [PMID:22460312].
Copaiba oil exhibited dose-dependent bactericidal activity against planktonic GBS strains, including those resistant to erythromycin and/or clindamycin [PMID:31866975].
Copaifera officinalis oil and kaurenoic acid caused antinociceptive effects in mice [PMID:31098702].
Copaiba essential oil delivered via a self-nanoemulsifying drug delivery system (SNEDDS) effectively reduced articular and systemic inflammation in rats [PMID:39883060].
A nanoemulsion of C. officinalis oil was evaluated for its ability to inhibit ZIKV in VERO cells in vitro [PMID:37676868].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 29193389 (2018) — Antimicrobial activity of copaiba oil (Copaifera ssp.) on oral pathogens: Systematic review. · Phytotherapy research : PTR
- 2.PMID: 21095089 (2011) — Validation of a gas chromatographic method to quantify sesquiterpenes in copaiba oils. · Journal of pharmaceutical and biomedical analysis
- 3.PMID: 37676868 (2023) — Synthesis of copaiba (Copaifera officinalis) oil nanoemulsion and the potential against Zika virus: An in vitro study. · PloS one
- 4.PMID: 31866975 (2019) — Hydrogel Containing Oleoresin From Copaifera officinalis Presents Antibacterial Activity Against Streptococcus agalactiae. · Frontiers in microbiology
- 5.PMID: 28194218 (2017)